Eli Lilly: FDA approves Kisinla for Alzheimer's disease

(CercleFinance.com) - Eli Lilly reports that the FDA has approved Kisunla (donanemab-azbt) as a monthly injection to treat adults with early-onset Alzheimer's disease (AD), including mild cognitive impairment (MCI) and mild dementia with confirmed amyloid pathology.


Kisunla, the first therapy targeting amyloid plaques that allows treatment to be stopped when the plaques are eliminated, could reduce costs and infusions.

Kisunla has shown significant results for early Alzheimer's patients, slowing clinical decline by 35% in those less advanced in the disease and by 22% in the overall population.

Copyright (c) 2024 CercleFinance.com. All rights reserved.